☆ 4.6 Editorial Material

Is genetic testing coming of age in advanced prostate cancer?

BJU INTERNATIONAL (2023)

Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?

Kenneth Chen et al.

Summary: Androgen deprivation therapy (ADT) has been the standard treatment for newly diagnosed metastatic prostate cancer, but the adoption of combination therapy is low despite evidence-based recommendations.

NATURE REVIEWS UROLOGY (2023)

添加到收藏夹

Article Oncology

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Meeting Abstract Oncology

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

Kim N. Chi et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?

Arpit Rao et al.

Summary: In the past decade, numerous new treatment options for advanced prostate cancer have been developed and approved. The combination therapy of androgen receptor (AR) and PARP proteins inhibition has shown promising early efficacy signals and has the potential for a breakthrough in the treatment of prostate cancer.

CANCERS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Mohammad Asim et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)

Dan Robinson et al.

CELL (2015)

添加到收藏夹

Is genetic testing coming of age in advanced prostate cancer?

相关参考文献

Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)

导出引文

分享论文